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Nonsegmental vitiligo is an acquired leukoderma characterized by the destruction of melanocytes.
Autoimmunity is the most widely accepted hypothesis to explain the pathogenesis of nonsegmental
vitiligo. Increased oxidative stress and decreased expression of E-cadherin may facilitate the loss of
melanocytes. Because vitiligo preferentially affects cosmetically sensitive regions such as the face, hands,
and genital area, it imposes signiﬁcant psychological and social burdens. In this review, we discuss recent
topics in the epidemiology, pathogenesis, genetic background, and therapeutic advances of non-
segmental vitiligo.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vitiligo is an acquired depigmenting disorder that should be differ-
entiated from congenital hypopigmentation such as albinism, pie-
baldism, dyschromatosis symmetrica hereditaria, and nevus
depigmentosus.1e3 Idiopathic guttate hypomelanosis, tinea versi-
color, and chemically induced leukoderma caused by phenols, cat-
echols, and rhododendrol should also be distinguished from
authentic vitiligo.1,3e5 Segmental vitiligo affecting a unilateral
dermatome-like cutaneous segment is less frequent than non-
segmental or generalized vitiligo.6 Occasionally, both nonsegmental
and segmental vitiligo appear in one patient (mixed type).6 Dysre-
gulation of the nervous system is hypothesized to be the cause of
segmental vitiligo.6Epidemiology
The prevalence of vitiligo is estimated at less than 1%.2e4,6,7 A
precise population-based epidemiological study by Howitz et al8
revealed that the prevalence of vitiligo was 0.38% (179/47,033) in
Denmark, peaking at 60e69 years of agewith amale to female ratio
of 1:1.13. Although selection bias should be considered in patient-e no ﬁnancial or non-ﬁnancial
erials discussed in this article.
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al Association. Published by Elsevibased studies, vitiligo was found in 1134 (1.68%) of 67,448 Japa-
nese dermatological patients, peaking at 66e75 years of age with a
male to female ratio of 1:1.37.9 Women are generally affected by
vitiligo more than (or equal to) men.1,10 In another study of 912,986
Japanese dermatological patients, congenital and acquired depig-
mented disorders affected 1748 (0.2%) and 6359 (0.7%) patients,
respectively, and 60% of total depigmented disorders consisted of
vitiligo.7 In Korea, the annual prevalence of vitiligo determined by
hospital-visiting ratewas 0.12% to 0.13%, with a male to female ratio
of 1:1.31 over a 3-year period.11Pathogenesis
While the pathogenesis of nonsegmental vitiligo remains poorly
understood, autoimmune stress and oxidative stress are currently
considered to work synergistically in the apoptosis or destruction
of melanocytes (Figure 1).1,3,12 Both humoral and cellular immunity
are involved in the development of nonsegmental vitiligo. Auto-
antibodies are variably detected against pigment cell antigens such
as tyrosinase and tyrosinase-related protein 1 and 2.1 At the center
of a vitiligo lesion, complete loss of melanocytes is observed.
Inﬁltration of macrophages, T cells and neutrophils is demon-
strated, especially in progressing perilesional skin. The majority of
epidermotropic T cells express cutaneous lymphocyte antigen
(skin-homing receptor) with an increased CD8/CD4 ratio and
interferon g production.1,13e16 Interferon g is known to inhibit
melanogenesis and to induce apoptosis of melanocytes (Figure 1).15
Furthermore, interferon a-2a-induced nonsegmental vitiligo occurser Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1 Pathogenesis of nonsegmental vitiligo. Lesional skin of vitiligo lacks melanocytes. Melanocyte cell death has multiple causes. Cellular and humoral immunity appear to be
involved in this cytotoxic process. The perilesional skin harbors multicellular inﬁltrates comprising CD4þ T cells, CD8þ T cells, macrophages, and neutrophils. CD8þ T cells together
with released interferon-g are cytotoxic to melanocytes. Loss of E-cadherin induces detachment and apoptosis of melanocytes. Increased oxidative stress (reactive oxygen species;
ROS) is detected in lesional skin, which facilitates apoptosis of E-cadherin-deﬁcient melanocytes. In addition, elevated ROS levels oxidize constituent enzymes in melanocytes, such
as tyrosinase, which may accelerate the production of anti-oxidized tyrosinase autoantibodies. The activation of Langerhans cells is also observed in lesional skin, which may
facilitate cellular and humoral immunity. More than 36 susceptible genes are reported. Six genes (LPP, HLA Class I gene region, IL2RA, IKZF4, C1QTNF6, and RNASET2-FGFR1OP-CCR6)
are shared between Caucasian and Chinese populations. Nonsegmental vitiligo is associated with other autoimmune diseases such as Hashimoto’s thyroiditis and pernicious
anemia. Four genes (PTPN22, RERE, IFIH1, and CTLA4) are associated with vitiligo in patients with other autoimmune diseases. Several microRNAs are also reported to be up- or
downregulated in nonsegmental vitiligo.
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in normal appearing skin of patients with nonsegmental vitiligo,
melanocytes tend to lack expression of E-cadherin; a molecule
essential to the adhesion of melanocytes to surrounding basal
keratinocytes.17 This abnormality is associated with the detach-
ment of the melanocytes from the basal to suprabasal layers in the
epidermis, leading to apoptosis of melanocytes (Figure 1).17
Increased oxidative stress (excessive reactive oxygen species)
with mitochondrial swelling is detected in the lesional keratino-
cytes of nonsegmental vitiligo (Figure 1).12,17 Low levels of anti-
oxidant enzymes have also been detected in the serum of vitiligo
patients.12 The inﬂammasome protein, nucleotide-binding
domain and leucine-rich repeat containing protein 1 (NLRP1), is
a key enzyme to mediate the activation of interleukin (IL)-1b. The
NLRP1 and IL-1b immunostaining in the perilesional skin of
nonsegmental vitiligo is signiﬁcantly associated with progressive
disease.18
Oxidative stress causes extensive alterations in conformation
and function of tyrosinase, which increases the antigenicity of
oxidized tyrosinase.19 In lesional skin, Langerhans cells are
increased in number and activated so that they may facilitate the
antigen-presenting process against the oxidized melanocyte anti-
gens.12,19,20 Additionally, oxidative stress or mechanical friction
further accelerates the detachment and apoptosis of melanocytes
with insufﬁcient expression of E-cadherin (Figure 1).17 This may
explain the frequent occurrence of Koebner's phenomenon in
vitiligo.21e23 Furthermore, decreased levels of copper and zinc may
be related to melanogenesis and oxidative stress because thesetrace elements, which are considered as antioxidants, are integral
parts of many metalloenzymes that are essential in the process of
melanogenesis.24
MicroRNAs (miRs) are short noncoding RNA molecules that
regulate gene expression, and contribute to biological processes
including apoptosis, cell cycle progression, and differentiation. To
date, nearly 2500 miRs have been found in humans.25 In lesional
skin, miR-1, miR-133a and miR-133b are signiﬁcantly upregulated
compared with controls in normal skin.26 Other studies have
shown that miR-16, miR-451, miR-224-3p and miR-4712-3p are
overexpressed and that miR-574-3p, miR-1274A, miR-3940-5p are
downregulated in the blood of nonsegmental vitiligo patients
compared with healthy controls (Figure 1).27,28 Different series of
miRs are likely to be operative in situ and in the circulation to
regulate the pathomechanism of vitiligo.Genetic background and comorbidity
Genetic background also plays a pivotal role in the pathogenesis of
nonsegmental vitiligo. Concordance rate of vitiligo was 23% among
22 monozygotic twin-pairs compared with 0% among dizygotic
twin-pairs.10 The reported frequency of vitiligo among ﬁrst-degree
relatives of 2078 Caucasian vitiligo probands was 18 times that of
the general population.10 As reviewed intensively, recent genome-
wide association and linkage studies have suggested at least 36
susceptibility loci in Caucasian populations.29,30 Chinese pop-
ulations have nine susceptibility loci, six of which are shared with
Caucasian populations: LPP, HLA Class I gene region, IL2RA, IKZF4,
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associated with other autoimmune diseases such as Hashimoto's
thyroiditis, pernicious anemia, Addison's disease, diabetes mellitus,
systemic lupus erythematosus, and inﬂammatory bowel dis-
ease.1,10,30,31 Comorbidity of vitiligo with lichen sclerosus and
antitumor necrosis factor a treatment are also reported.32e34 Four
genes, PTPN22, RERE, IFIH1, and CTLA4, are recognized vitiligo sus-
ceptibility loci for patients with systemic autoimmune diseases
(Figure 1).29 Vitiligo is known to appear in animals such as pigs,
horses, and chickens.35Therapeutic approach
Because vitiligo preferentially affects cosmetically sensitive regions
such as the face, hands, and genital area, it imposes signiﬁcant
psychological and social burdens.7,36 Therapeutic guidelines have
been published in different countries, with similar concepts and
evidence.6,7,37e39 Beneﬁcial effects are evident in topical cortico-
steroids and topical calcineurin inhibitors; phototherapies
including narrowband ultraviolet B (UVB), psoralen plus ultraviolet
A (PUVA), and excimer light; oral steroid minipulse; surgical pro-
cedures with punch or epidermal grafting; and camouﬂage.6,7,37e41
Repigmentation is assumed to occur due to the migration of mel-
anocytic stem cells present in the lower part of the bulge (peri-
follicular repigmentation) and/or the direct migration of
perilesional melanocytes (edge repigmentation).38 Several inter-
national scales have been developed to measure the severity
(Vitiligo Extent Score),42 quality of life (Vitiligo Impact Patient
Scale),43 and patient-reported outcome evaluation (Vitiligo Noti-
ceability Scale).44 Although narrowband UVB has been reported to
be more effective than PUVA,45 a recent meta-analysis could not
prove the superiority as evaluated by >75% repigmentation.41
Treatment with topical calcipotriol and oral PUVA resulted in
signiﬁcantly higher percentages of both initial (81%) and complete
pigmentation (63%), compared with placebo and PUVA (7% and
15%, respectively).46 Similarly, the addition of topical tacalcitol to
narrowband UVB improved the extent of repigmentation and
increased the response rate more than narrowband UVB alone.47
Recent systematic reviews have also reported that the combina-
tion therapy with topical calcineurin inhibitors and narrowband
UVB or 308 nm excimer laser/light irradiation are more effective for
vitiligo than monotherapy with narrowband UVB or 308 nm exci-
mer laser/light irradiation.48,49 Oral minipulse of betamethasone
plus narrowband UVB was signiﬁcantly superior to treatment with
oral minipulse of betamethasone alone.50 However, the above-
mentioned standard treatments do not fully satisfy the quality of
life of patients in our daily clinics. Novel therapeutic approaches are
deﬁnitely necessary. In this context, oral tofacitinib, a Janus kinase
1/3 inhibitor, may be a promising agent in the near future.51
In conclusion, recent clinical, genetic, and experimental studies
further stress the signiﬁcance of autoimmunity and oxidative
milieu in the pathogenesis of vitiligo. New drugs targeting the
immune response in combination with antioxidant agents may
enhance the therapeutic potential with or without conventional
treatments.References
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